NeoImmuneTech Statistics
Total Valuation
NeoImmuneTech has a market cap or net worth of KRW 23.35 billion. The enterprise value is 5.83 billion.
Market Cap | 23.35B |
Enterprise Value | 5.83B |
Important Dates
The last earnings date was Thursday, May 15, 2025.
Earnings Date | May 15, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
NeoImmuneTech has 19.77 million shares outstanding. The number of shares has increased by 0.02% in one year.
Current Share Class | n/a |
Shares Outstanding | 19.77M |
Shares Change (YoY) | +0.02% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 4.78% |
Owned by Institutions (%) | 4.79% |
Float | 14.64M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 127.18 |
PB Ratio | 0.71 |
P/TBV Ratio | 0.88 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -0.16 |
EV / Sales | 31.74 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -0.15 |
Financial Position
The company has a current ratio of 1.45, with a Debt / Equity ratio of 0.33.
Current Ratio | 1.45 |
Quick Ratio | 1.24 |
Debt / Equity | 0.33 |
Debt / EBITDA | n/a |
Debt / FCF | -0.29 |
Interest Coverage | -57.04 |
Financial Efficiency
Return on equity (ROE) is -75.37% and return on invested capital (ROIC) is -41.66%.
Return on Equity (ROE) | -75.37% |
Return on Assets (ROA) | -34.22% |
Return on Invested Capital (ROIC) | -41.66% |
Return on Capital Employed (ROCE) | -107.01% |
Revenue Per Employee | 2.24M |
Profits Per Employee | -457.75M |
Employee Count | 82 |
Asset Turnover | 0.00 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.97% in the last 52 weeks. The beta is 0.97, so NeoImmuneTech's price volatility has been similar to the market average.
Beta (5Y) | 0.97 |
52-Week Price Change | -31.97% |
50-Day Moving Average | 1,213.96 |
200-Day Moving Average | 1,262.50 |
Relative Strength Index (RSI) | 40.75 |
Average Volume (20 Days) | 5,062,348 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NeoImmuneTech had revenue of KRW 183.62 million and -37.54 billion in losses. Loss per share was -379.66.
Revenue | 183.62M |
Gross Profit | 3.09B |
Operating Income | -38.06B |
Pretax Income | -37.58B |
Net Income | -37.54B |
EBITDA | -34.10B |
EBIT | -38.06B |
Loss Per Share | -379.66 |
Balance Sheet
The company has 28.46 billion in cash and 10.94 billion in debt, giving a net cash position of 17.52 billion or 886.23 per share.
Cash & Cash Equivalents | 28.46B |
Total Debt | 10.94B |
Net Cash | 17.52B |
Net Cash Per Share | 886.23 |
Equity (Book Value) | 32.97B |
Book Value Per Share | 333.48 |
Working Capital | 10.37B |
Cash Flow
In the last 12 months, operating cash flow was -36.51 billion and capital expenditures -1.84 billion, giving a free cash flow of -38.35 billion.
Operating Cash Flow | -36.51B |
Capital Expenditures | -1.84B |
Free Cash Flow | -38.35B |
FCF Per Share | -1,939.56 |
Margins
Gross Margin | n/a |
Operating Margin | -20,725.74% |
Pretax Margin | -20,466.31% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
NeoImmuneTech does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.02% |
Shareholder Yield | n/a |
Earnings Yield | -160.74% |
FCF Yield | -164.23% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |